Toxicities Rare After Two Weeks of CAR T-Cell Therapy Infusion
Nonrelapse mortality was driven by ICANS in early follow-up period, followed by infection through three months
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.